KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Total Liabilities (2016 - 2025)

Exact Sciences (EXAS) has disclosed Total Liabilities for 16 consecutive years, with $3.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 1.88% to $3.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 billion, a 1.88% decrease, with the full-year FY2025 number at $3.5 billion, down 1.88% from a year prior.
  • Total Liabilities was $3.5 billion for Q4 2025 at Exact Sciences, up from $3.4 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $3.5 billion in Q3 2024 to a low of $3.1 billion in Q1 2021.
  • A 5-year average of $3.3 billion and a median of $3.3 billion in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 60.41% in 2021, then fell 4.39% in 2025.
  • Exact Sciences' Total Liabilities stood at $3.3 billion in 2021, then dropped by 3.44% to $3.2 billion in 2022, then rose by 4.47% to $3.3 billion in 2023, then increased by 6.01% to $3.5 billion in 2024, then fell by 1.88% to $3.5 billion in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Total Liabilities are $3.5 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.3 billion (Q2 2025).